Cancer Advances Acquires the Intellectual Property for a Suite of Products that Enhance the Immune System in Treatment of Gastric, Pancreatic, and Colorectal Cancers
“We are excited about continuing the development of PAS in pancreatic and gastric cancers,” said
The purchase agreement includes multiple patents as well as clinical and safety data for the more than 1,100 patients who have been treated with PAS to date for gastric, pancreatic, and colorectal cancers. Cancer Advances will be seeking additional funding for the company as well as potential development partners.
PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a central role of both of these endogenous compounds in the development and progression of gastrointestinal tumors. Prior to the acquisition of this technology by Cancer Advances, more than
About Cancer Advances
About Cato Research Ltd.
Founded in 1988 by
About Cato BioVentures
Cato BioVentures is the venture capital affiliate of Cato Research. For nearly 20 years, Cato BioVentures has assisted entrepreneurs and established management teams in building successful life science companies. Through strategic Contract Research Organization (CRO) service agreements with Cato Research,
SOURCE Cancer Advances, Inc.